CNCR - (Loncar Cancer Immunotherapy ETF)

 CNCRのチャート


 CNCRの企業情報

symbol CNCR
会社名
分野(sector)   
産業(industry)   
業種   
概要 事業概要 --     
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear ―年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/cncr
adr_tso
EBITDA EBITDA ー
終値(lastsale) 23.16
時価総額(marketcap) 52110000
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 CNCRのテクニカル分析


 CNCRのニュース

   Top Momentum ETF Plays: MNA, GREK, XPH, CNCR, EWJ, BJK, HEFA  2020/09/16 13:53:33 The Street
Top 25 momentum candidates that are displaying positive price movement, improving relative strength and strong technical signals.
   3 ETFs For More Moderna Bets  2020/05/19 13:29:37 Benzinga
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA ) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress. Those headlines prompted some analysts to say Moderna could be the first to market with a credible vaccine for the sometimes-fatal respiratory illness, and with those comments came at least a trio of bullish price target revisions into triple-digit territory. For all the ebullience surrounding Moderna this year — and there's been plenty as highlighted by a 2020 climb of 309% — the stock isn't often mentioned in relation to exchange traded funds. A few ETFs have robust Moderna holdings. The stock closed at $80 Monday, and with some price targets residing in the $100 to $105 area, there could be more upside ahead, meaning the following ETFs could be worth considering. Loncar Cancer Immunotherapy ETF (CNCR) Sixty-two ETFs have some exposure … Full story available on Benzinga.com
   A Ripple In Generics?  2019/03/08 21:37:19 Seeking Alpha
   Currents Of Disruption: Focusing On Fundamentals In Biotech  2019/02/08 09:08:31 Seeking Alpha
   Top Momentum ETF Plays: MNA, GREK, XPH, CNCR, EWJ, BJK, HEFA  2020/09/16 13:53:33 The Street
Top 25 momentum candidates that are displaying positive price movement, improving relative strength and strong technical signals.
   3 ETFs For More Moderna Bets  2020/05/19 13:29:37 Benzinga
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA ) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress. Those headlines prompted some analysts to say Moderna could be the first to market with a credible vaccine for the sometimes-fatal respiratory illness, and with those comments came at least a trio of bullish price target revisions into triple-digit territory. For all the ebullience surrounding Moderna this year — and there's been plenty as highlighted by a 2020 climb of 309% — the stock isn't often mentioned in relation to exchange traded funds. A few ETFs have robust Moderna holdings. The stock closed at $80 Monday, and with some price targets residing in the $100 to $105 area, there could be more upside ahead, meaning the following ETFs could be worth considering. Loncar Cancer Immunotherapy ETF (CNCR) Sixty-two ETFs have some exposure … Full story available on Benzinga.com
   A Ripple In Generics?  2019/03/08 21:37:19 Seeking Alpha
   Currents Of Disruption: Focusing On Fundamentals In Biotech  2019/02/08 09:08:31 Seeking Alpha

 関連キーワード  (― 米国株 CNCR Loncar Cancer Immunotherapy ETF)

 twitter  (公式ツイッターやCEOツイッターなど)